The intracellular pharmacokinetics of terminally capped peptides.
about
Artificial disulfide-rich peptide scaffolds with precisely defined disulfide patterns and a minimized number of isomers.Endosomolytic Nano-Polyplex Platform Technology for Cytosolic Peptide Delivery To Inhibit Pathological Vasoconstriction.MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia.An in silico model of cytotoxic T-lymphocyte activation in the lymph node following short peptide vaccination.
P2860
The intracellular pharmacokinetics of terminally capped peptides.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The intracellular pharmacokinetics of terminally capped peptides.
@ast
The intracellular pharmacokinetics of terminally capped peptides.
@en
type
label
The intracellular pharmacokinetics of terminally capped peptides.
@ast
The intracellular pharmacokinetics of terminally capped peptides.
@en
prefLabel
The intracellular pharmacokinetics of terminally capped peptides.
@ast
The intracellular pharmacokinetics of terminally capped peptides.
@en
P2093
P356
P1476
The intracellular pharmacokinetics of terminally capped peptides.
@en
P2093
Emer S Ferro
Ivo R Ruttekolk
J Joris Witsenburg
Petra H M Bovee-Geurts
Roland Brock
Wouter P R Verdurmen
P304
P356
10.1021/MP200331G
P407
P577
2012-04-24T00:00:00Z